Associations between Skin Diseases and Quality of Life: A Comparison of Psoriasis, Vitiligo, and Alopecia Areata

  • Mahsa Ghajarzadeh Mail Brain and Spinal Injury Repair Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Maryam Ghiasi Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Shahrbanoo Kheirkhah Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Psoriasis, Vitiligo, Alopecia areata, Depression, Quality of life, Iran


The goal of this study was to compare depression and quality of life in three auto immune diseases: psoriasis, vitiligo, and alopecia areata. From January 2009 until January 2010, 300 patients (100 with alopecia areata, 100 with psoriasis and 100 with vitiligo) who were randomly selected (by simple random selection) from outpatient clinic of Razi Hospital (Center of Skin Diseases of Tehran University of Medical Sciences) were asked to answer to Beck Depression Inventory (BDI), SF-36 and Dermatology Life Quality Index (DLQI) questionnaires. DLQI scores were significantly higher in psoriasis cases than others (12.8 ± 6.1, P<0.0001) and SF-36 score were significantly lower (59.8 ± 19.5, P=0.007), both indicating poor quality of life. Significant correlation was found between DLQI and BDI in all disease groups (r=0.44, P<0.001). BDI scores were the highest in psoriasis group but this difference was not significant (P=0.2). Based on these results, dermatologists should consider psychological aspects of autoimmune skin diseases.


Taïeb A, Picardo M; VETF Members. The definition andm assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20(1):27-35.

Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry 1979;1(1):73-7.

Porter JR, Beuf AH, Lerner A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with "normal" control subjects, with psoriasis patients, and withpatients with other pigmentary disorders. J Am Acad Dermatol 1986;15(2 Pt 1):220-4.

Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352(18):1899-912.

Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004;9(2):131-5.

Kanikowska A, Kramer L, Pawlaczyk M. Quality of life in Polish patients with psoriasis. J Eur Acad Dermatol Venereol 2009;23(1):92-3. Epub 2008 Apr 1.

Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007;215(1):17-27.

Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992;128(5):702.

Colón EA, Popkin MK, Callies AL, Dessert NJ, HordinskyMK. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 1991;32(3):245-51.

Güleç AT, Tanriverdi N, Dürü C, Saray Y, Akçali C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol2004;43(5):352-6.

Finlay AY, Khan GK. Dermatology Life Quality Index(DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-6.

Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY.DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2004;4:8.

Jafari H, Lahsaeizadeh S, Jafari P, Karimi M. Quality of life in thalassemia major: reliability and validity of the Persian version of the SF-36 questionnaire. J Postgrad Med 2008;54(4):273-5.

Ghassemzadeh H, Mojtabai R, Karamghadiri N,Ebrahimkhani N. Psychometric properties of a Persianlanguage version of the Beck Depression Inventory: Second edition: BDI-II-PERSIAN. Depress Anxiety 2005;21(4):185-92.

Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005;152(6):1165-72.

Jobanputra R, Bachmann M. The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa. Int J Dermatol 2000;39(11):826-31.

Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996;10(6):644-53.

Kent G, al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996;21(5):330-3.

Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003;148(2):373-4.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50.

Gladman DD. Psoriatic arthritis. Dermatol Ther 2004;17(5):350-63.

Fortune DG, Richards HL, Main CJ, Griffiths CE. What patients with psoriasis believe about their condition. J Am Acad Dermatol 1998;39(2 Pt 1):196-201.

Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life. Ann Dermatol 2010;22(4):389-96.

How to Cite
Ghajarzadeh M, Ghiasi M, Kheirkhah S. Associations between Skin Diseases and Quality of Life: A Comparison of Psoriasis, Vitiligo, and Alopecia Areata. Acta Med Iran. 50(7):511-515.